FGFernando U. Garcia

Fernando U. Garcia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fernando U. Garcia has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 847 Establishment and Characterization of a Novel Gallbladder Cell Line to Study Gallbladder Cancer and Gallstones

    by Mohammad Z. Abedin, Nandita Suresh, Samuel Jun, Will Sun, Muhammad T. Rahman, Fernando U. Garcia, Mark E. Stearns

  • Fine-needle aspiration of adult small-round-cell tumors studied with flow cytometry

    by Marino E. Leon, J. Steve Hou, Lorenzo M. Galindo, Fernando U. Garcia

    Immunophenotypic study is critical for the diagnosis of adult small‐round‐cell tumors (SRCTs). We describe three patients with Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) and one patient with neuroblastoma in which flow cytometry immunophenotyping (FCI) on the fine‐needle aspirate (FNA) and bone marrow aspirate (BMA) demonstrated an abnormal population of cells that were CD45− and CD16/CD56+. Four patients with mean age of 30 years, three male and one female, clinically suspicious for a lymphoma or SRCT are described. FNA, BMA, and biopsy specimens were obtained for routine cytologic and histologic evaluation. Fresh tissue was studied by FCI. In all cases, the cytology smears showed small cells with round nuclei, slightly irregular nuclear membranes, fine chromatin, and scant cytoplasm. FCI showed CD16/56+ and CD45− neoplastic cells in all cases. In one case, 76% of these cells were CD99+. The diagnoses of ES/PNET were confirmed by immunohistochemical, ultrastructural, and cytogenetic studies. ES/PNET in FNA and BMA can be efficiently and rapidly diagnosed by combining cytologic examination with FCI using a panel including CD45, CD16/56, and CD99. Diagn. Cytopathol. 2004;31:147–154.


    • 1 March 2003
      • Vol. 9  (3) , 1191-9

    Interleukin 10 blocks matrix metalloproteinase-2 and membrane type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines.

    by Mark E Stearns, Min Wang, Youji Hu, Fernando U Garcia, JohnG Rhim

    Insulin-like growth factor (IGF) I has been shown previously to up-regulate matrix metalloproteinase-2 (MMP-2) production, whereas the interleukin (IL) 10/IL-10 receptor axis has been found to down-regulate MMP-2 synthesis in tumor cells. In this paper, we showed that IL-10 activation of the IL-10 receptor blocked MMP-2 and membrane type 1 (MT1) -MMP transcription and protein synthesis in nonimmortalized primary human prostate cell strains (i.e., HPCA-10a and HPCA-10c) derived from high-grade cancer. Northern blots, Western blots, and ELISAs showed that IL-10 suppressed IGF-I induction of MMP-2 and MT1-MMP mRNA synthesis in these cell strains (P < 0.001). Inhibition studies with IL-10 and IGF-I receptor antibodies plus transfections experiments with IL-10 sense, and IGF-I receptor antisense constructs confirmed these results. Finally, transient transfection experiments and chloramphenicol acetyltransferase assays with different regions of the 5' promoter region of the MMP-2 gene (-1659 to -555 bp) additionally showed that IGF-I stimulated p53-dependent plasmid catecholamine acetyltransferase activity and that IL-10 blocked IGF-I-induced plasmid catecholamine acetyltransferase activity. Electrophoretic mobility shift assays revealed that IL-10 induced protein(s) binding to a putative "silencer element" (-1309 to -555 fragment) downstream of the p53 binding site (-1649 to -1640). The data show that IL-10 blocks IGF-I activation of MMP-2 and MT1-MMP mRNA expression and protein synthesis in primary prostate cell strains.


  • Open Access

    Increased Cellularity of Tumor-Encased Native Vessels in Prostate Carcinoma Is a Marker for Tumor Progression

    by Fernando U Garcia, Cullen A Taylor, J Steve Hou, Daniel B Rukstalis, Mark E Stearns